1. Home
  2. UTHR vs LBRDK Comparison

UTHR vs LBRDK Comparison

Compare UTHR & LBRDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • LBRDK
  • Stock Information
  • Founded
  • UTHR 1996
  • LBRDK 2014
  • Country
  • UTHR United States
  • LBRDK United States
  • Employees
  • UTHR N/A
  • LBRDK N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • LBRDK Cable & Other Pay Television Services
  • Sector
  • UTHR Health Care
  • LBRDK Telecommunications
  • Exchange
  • UTHR Nasdaq
  • LBRDK Nasdaq
  • Market Cap
  • UTHR 13.8B
  • LBRDK 13.0B
  • IPO Year
  • UTHR 1999
  • LBRDK N/A
  • Fundamental
  • Price
  • UTHR $312.23
  • LBRDK $63.62
  • Analyst Decision
  • UTHR Buy
  • LBRDK
  • Analyst Count
  • UTHR 13
  • LBRDK 0
  • Target Price
  • UTHR $382.00
  • LBRDK N/A
  • AVG Volume (30 Days)
  • UTHR 762.5K
  • LBRDK 2.1M
  • Earning Date
  • UTHR 07-30-2025
  • LBRDK 08-07-2025
  • Dividend Yield
  • UTHR N/A
  • LBRDK N/A
  • EPS Growth
  • UTHR 17.94
  • LBRDK 36.76
  • EPS
  • UTHR 25.63
  • LBRDK 7.58
  • Revenue
  • UTHR $3,077,800,000.00
  • LBRDK $1,052,000,000.00
  • Revenue This Year
  • UTHR $14.37
  • LBRDK $6.59
  • Revenue Next Year
  • UTHR $6.59
  • LBRDK $2.22
  • P/E Ratio
  • UTHR $12.18
  • LBRDK $8.39
  • Revenue Growth
  • UTHR 17.62
  • LBRDK 7.24
  • 52 Week Low
  • UTHR $266.98
  • LBRDK $54.64
  • 52 Week High
  • UTHR $417.82
  • LBRDK $97.38
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 58.33
  • LBRDK 39.72
  • Support Level
  • UTHR $303.59
  • LBRDK $60.71
  • Resistance Level
  • UTHR $317.31
  • LBRDK $62.21
  • Average True Range (ATR)
  • UTHR 7.91
  • LBRDK 1.52
  • MACD
  • UTHR 0.90
  • LBRDK 1.23
  • Stochastic Oscillator
  • UTHR 80.53
  • LBRDK 80.54

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About LBRDK Liberty Broadband Corporation Class C

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.

Share on Social Networks: